Hantavirus vs COVID-19 — Side-by-Side Comparison
Hantavirus and COVID-19 share a few early symptoms but are caused by completely unrelated viruses, with different transmission routes, severity, and treatment. This page covers the key differences clinicians, patients, and travellers should know.
Hantavirus vs COVID-19 — at-a-glance comparison
| Feature | Hantavirus | COVID-19 |
|---|---|---|
| Causative agent | Orthohantavirus (Hantaviridae) | SARS-CoV-2 (Coronaviridae) |
| Discovered | 1976 (Hantaan); 1993 (Sin Nombre) | 2019 |
| Reservoir | Specific rodent species | Bats (likely), plus circulating in humans |
| Primary transmission | Aerosolised rodent excreta | Respiratory droplets, person-to-person |
| Person-to-person? | Andes virus only | Yes, the defining feature |
| Incubation | 1-8 weeks | 2-14 days |
| Prodrome | 3-7 days of fever, myalgia, GI symptoms | 1-3 days of fever, cough, fatigue |
| Loss of smell/taste | No | Common |
| Thrombocytopenia | Universal in HPS | Mild if any |
| Pulmonary deterioration | Rapid (12-48 hours) | Slower (days to weeks) |
| Lung pathology | Non-cardiogenic capillary leak | Diffuse alveolar damage, ARDS |
| Case-fatality | 30-50% (HPS), under 1% (Puumala) | ~1% overall |
| Vaccine | Only regional (Korea, China) | Multiple licensed worldwide |
| Specific antiviral | None (ribavirin in HFRS only) | Paxlovid, remdesivir, molnupiravir |
| Annual global cases | ~150,000-200,000 | Tens of millions |
| Annual global deaths | ~500-1,200 | Hundreds of thousands |
How clinicians distinguish them
In a febrile patient with respiratory symptoms, several discriminators help narrow the differential:
- Exposure history. Rodent contact, occupational exposure to rodent-infested structures, travel to endemic areas, or matching the MV Hondius itinerary point strongly to hantavirus. Close contact with a confirmed COVID-19 case points to COVID-19.
- Blood smear and CBC. Thrombocytopenia, left-shifted white cells, and circulating immunoblasts on blood smear are highly suggestive of hantavirus (the classical haematological triad).
- Loss of smell or taste. Specific to COVID-19 and not seen in hantavirus.
- SARS-CoV-2 testing. A positive lateral flow or PCR rapidly confirms COVID-19. A negative test in a critically ill patient should prompt consideration of alternative diagnoses including hantavirus.
- Chest imaging. Both can show bilateral infiltrates. HPS classically shows rapid-onset capillary-leak pulmonary oedema; COVID-19 shows progressive ground-glass opacities over days.
- Speed of deterioration. Hantavirus HPS can go from cough to respiratory failure in 12-48 hours. COVID-19 deterioration is typically slower.
When BOTH should be tested for
Any patient with fever, respiratory symptoms, AND a credible rodent exposure or relevant travel history should be tested for both hantavirus and COVID-19. The two are not mutually exclusive — both should be considered until ruled out.
Treatment comparison
| Treatment | Hantavirus (HPS) | COVID-19 |
|---|---|---|
| Specific antiviral | None licensed | Paxlovid (early), remdesivir, molnupiravir |
| Monoclonal antibodies | ANDV mAbs in Phase 1/2 | Multiple licensed (early use) |
| Steroids | Not standard | Dexamethasone in severe disease |
| Mechanical ventilation | Standard ARDS protocols | Standard ARDS protocols |
| Prone positioning | Yes, in refractory hypoxia | Yes, in refractory hypoxia |
| ECMO | Outcome-changing, refer early | Used in refractory cases |
| Restrictive fluids | Critical (non-cardiogenic oedema) | Useful in ARDS |
For travellers and the worried well
For most people in most places, COVID-19 is the much more likely cause of a febrile respiratory illness. Hantavirus should be considered only with a genuinely credible exposure history — not just being in an endemic country without specific high-risk activities.
If you have been on MV Hondius, follow the incident-specific guidance for self-monitoring and clinical care.
Open the live hantavirus outbreak map →
Frequently asked questions
Is hantavirus the same as COVID-19?
No. Hantavirus and COVID-19 are caused by completely unrelated viruses from different families. Hantavirus is Hantaviridae (an RNA virus carried by rodents). COVID-19 is Coronaviridae (an RNA virus that spread person-to-person). The symptoms overlap superficially but the diseases differ in transmission, severity, treatment, and prevention.
How do you tell hantavirus from COVID-19?
Clinical clues that favour hantavirus: rapid progression to non-cardiogenic pulmonary oedema with shock; thrombocytopenia (low platelets); recent rodent exposure or travel to endemic area; severe muscle pain especially in the thighs. Clues favouring COVID-19: loss of smell or taste; close-contact history with a confirmed case; positive lateral flow or PCR. Both can present with fever, cough, fatigue, and GI symptoms in the early days.
Is hantavirus more deadly than COVID-19?
Per case, yes — substantially. Hantavirus Pulmonary Syndrome has 30-50% case-fatality. COVID-19 has approximately 1% case-fatality overall in the Omicron era (varies by age and immunity). But COVID-19 has caused vastly more deaths globally because it spreads efficiently between people. Hantavirus does not.
Can you have hantavirus and COVID-19 at the same time?
Theoretically yes — they're caused by completely different viruses, so dual infection is biologically possible. No co-infection cases have been prominently documented, but the rapid progression of HPS likely means many co-infections would be misdiagnosed as severe COVID-19 unless hantavirus was specifically considered.
Did COVID-19 increase hantavirus cases?
Probably yes, indirectly. Lockdowns and rural migration during COVID-19 led to more outdoor and rural activity in some populations, with associated rodent exposure. Several countries reported small spikes in hantavirus cases during 2020-2021. The data are not definitive.
Do COVID-19 vaccines protect against hantavirus?
No. COVID-19 vaccines target SARS-CoV-2 spike protein and provide no cross-protection against hantavirus, which is from a completely different viral family.
Can a hantavirus patient be cared for in a COVID-19 ward?
For Sin Nombre, Puumala, and most hantaviruses — yes, with standard precautions. For Andes virus — no, ANDV-HPS patients require droplet + contact precautions and ideally negative-pressure isolation because of person-to-person transmission risk.
Has hantavirus mortality dropped because of COVID-era ICU improvements?
Plausibly. Many of the ICU practices refined during COVID-19 (lung-protective ventilation, prone positioning, early ECMO referral, restrictive fluids in ARDS) directly apply to severe HPS. Whether case-fatality has measurably dropped post-COVID is hard to establish given the small case numbers.